Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.94)
# 3,193
Out of 4,981 analysts
97
Total ratings
36.71%
Success rate
-6.74%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.60 | +92.31% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.00 | +150.00% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.27 | +164.32% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $18.57 | +142.33% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $69.53 | +20.81% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $114.55 | -3.97% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $39.15 | -2.94% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $15.74 | -4.70% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $76.90 | -31.08% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.05 | +387.80% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $46.55 | +50.38% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $0.20 | +885.71% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.93 | +884.46% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.82 | +226.46% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.25 | +361.54% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $41.34 | -12.91% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.12 | +461.80% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.81 | +17.10% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $9.05 | +286.74% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.84 | +438.92% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.52 | +1,873.68% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.14 | +1,654.39% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $4.09 | +144.50% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.53 | +175.65% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.77 | +1,312.43% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $6.17 | -71.64% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $19.97 | +0.15% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.58 | -5.06% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.90 | +2,147.19% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.08 | +394.35% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.95 | +6,185.36% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.75 | +554.55% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.60
Upside: +92.31%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.00
Upside: +150.00%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.27
Upside: +164.32%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $18.57
Upside: +142.33%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $69.53
Upside: +20.81%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $114.55
Upside: -3.97%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $39.15
Upside: -2.94%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $15.74
Upside: -4.70%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $76.90
Upside: -31.08%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.05
Upside: +387.80%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $46.55
Upside: +50.38%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $0.20
Upside: +885.71%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.93
Upside: +884.46%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.82
Upside: +226.46%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.25
Upside: +361.54%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $41.34
Upside: -12.91%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.12
Upside: +461.80%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.81
Upside: +17.10%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $9.05
Upside: +286.74%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.84
Upside: +438.92%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.52
Upside: +1,873.68%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.14
Upside: +1,654.39%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $4.09
Upside: +144.50%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $6.53
Upside: +175.65%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.77
Upside: +1,312.43%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $6.17
Upside: -71.64%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $19.97
Upside: +0.15%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.58
Upside: -5.06%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.90
Upside: +2,147.19%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $7.08
Upside: +394.35%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $0.95
Upside: +6,185.36%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.75
Upside: +554.55%